# Annual General Meeting

PATRYS™ LIMITED

*30 November 2011*

**Dr. Marie Roskrow**
**Chief Executive Officer**

**ASX: PAB**

# Safe Harbour Statement

The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (**Patrys**) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other entity or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securities may trade. In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Patrys securities. It is not for general distribution or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obligation to advise of changes or updates to any such materials.

These materials are not exhaustive of all of the information a potential investor or their professional adviser would require. Nor do these materials take into account any specific objectives, financial situation or needs of investors. In addition, the past performance of Patrys cannot be assumed as indicative of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securities you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Where this presentation does contain any forward looking statements, those statements are only made as the date of the presentation and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward looking statement. This is particularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising potential drugs intended for safe and effective for human treatments or therapies.

# Corporate Overview

## KEY STATISTICS – 31 OCTOBER 2011 (A$)

| | |
|---|---|
| ASX Code | PAB |
| Current share price | $0.057 |
| 52 Week High | $0.18 |
| 52 Week Low | $0.05 |
| Shares on Issue | 249,213,898 |
| Market Capitalisation | $14.2 m |
| Cash (30 Sep 2011) | $4.4 m |

## RECENT NEWS

**Sept. 2011 -** PAT-SM6 shows promise in additional cancer indications in preclinical studies

Second site for melanoma trial

Significant survival benefit for PAT-SC1 treated patients

**August 2011 -** PAT-SM6 detected in patient tumours

PAT-SM6 shows promise in multiple myeloma

**June 2011 -** PAT-SM6 inhibits metastases in melanoma cancer model

## 1 YEAR SHARE PERFORMANCE




## SHAREHOLDERS



# Pipeline Progress – Past 12 months

*Patrys has moved from being a preclinical to a clinical-stage oncology company*

| | |
|---|---|
| **PAT-SM6** | |
| **Clinical:** | **Phase 1 single-dose melanoma study commenced August 2010**<br>**➢Safe in all treated patients to date**<br>**➢Detected presence of PAT-SM6 in tumours of 2 treated patients**<br>**➢Some evidence of apoptosis in tumours post treatment** |
| **Preclinical:** | **Shown to inhibit metastases in melanoma xenograft model**<br>**Shown promise in multiple myeloma and OVCAR-3 xenograft model** |
| **PAT-LM1** | |
| **Preclinical:** | **Moved into scale-up GMP manufacturing facility (Laureate, USA)** |
| **Other:** | **US patent covering PAT-LM1 and similar structures binding NONO target** |
| **PAT-SC1** | |
| **Preclinical:** | **Moved into PERC.6 cell line in preparation for GMP manufacturing and out-licensing** |
| **Other:** | **Patent granted in Japan covering modified CD55 = target for PAT-SC1**<br>**Orphan Status confirmed by U.S. FDA** |

# Capital Raising

## Details of the Offer

| | |
|---|---|
| **Amount:** | **$3 million (Patrys reserves the right for overs of up to $2 million)** |
| **Issue Price:** | **3 cents per share** |
| **Method:** | **Placement to institutional and sophisticated investors** |
| | **37 million shares under 15% placement capacity** |
| | **Balance subject to shareholder approval at EGM** |

## Use of Funds

- **Conclude the ongoing Phase I single-dose melanoma clinical trial**
- **Support a PAT-SM6 Phase I/IIa open label multi-dose multiple myeloma clinical trial**
- **Support business development and licensing activities in respect of PAT-SC1**
- **Further prepare PAT-LM1 for clinical trial and/or partnering**
- **Progress the pipeline through internal R&D**

# PAT-SM6 Melanoma Trial

- Single dose, dose-escalating, trial of PAT-SM6 in N=9 patients with recurrent in-transit cutaneous melanoma
- Royal Adelaide Hospital and Princess Alexandra Hospital, Brisbane currently enrolling
- Three dose cohorts (0.15, 0.3, 0.6mg/kg), i.v. administration
- Currently in final cohort; expect completion next 2 months
- No adverse events reported to date
- Presence of PAT-SM6 detected in post-treatment biopsies of 2 patients
- Early indication of apoptosis (cell death) in post-treatment biopsies

# PAT-SM6 Melanoma Trial

PATRYS LIMITED




Melanoma patient tumour biopsies were collected before and after treatment with PAT-SM6, fixed in formalin and embedded in paraffin. An antibody specific for PAT-SM6 (PAT-SM6 anti Idiotype antibody) was used to detect the infused antibody in the tumours. Biopsies taken after treatment with PAT-SM6 show positive staining results, indicating the presence of PAT-SM6 in the tumor

# Multiple Myeloma Opportunity

- A cancer of the plasma cells in bone marrow. These cells grow out of control and form tumours in solid bone
- Estimated to be more than 200,000 cases worldwide and incidence increasing
- 5 year survival of approx. 40% (10yr≈20%). Despite new marketed therapies, disease remains largely incurable and fatal
- Market expected to more than double from ≈$2.1B (2008) to >$5B (2018)
- MM market dominated by 3 products:
  - Revlimid (net sales $2.5B in 2010)
  - Velcade (net sales $500M in 2010)
  - Thalidomide(net sales $390M in 2010)
- Several MAbs currently in clinical development but none approved to date. Likely to be used in combination therapies
- Significant interest in MM from both large pharmaceutical and biotechnology companies

# PAT-SM6 Multiple Myeloma Preclinical Data

- GRP78 (PAT-SM6 target) is expressed on MM tissues
- PAT-SM6 binds to both MM patient bone marrow (N=20/20) and MM cell lines (N=5/5)
- Treatment of patient tissues and cell lines with PAT-SM6 leads to significant cell death
- Cell death was increased by adding complement to the cell cultures resulting in significant complement dependent cytotoxicity (CDC)
- Preclinical studies ongoing, planning a Phase I/IIa study for 1HCY2012

# PAT-SM6 Multiple Myeloma Preclinical Data

- Patient tissue sourced from 11 patients at primary diagnosis, 9 with relapsed disease and 4 healthy controls
- Immunohistochemical staining on bone marrow sections revealed binding of PAT-SM6 in 20/20 MM patients (primary and relapsed disease)



# PAT-SM6 Multiple Myeloma Trial Design

- Phase I/IIa open-label multi-dose trial in relapsed and multi-resistant patients (N=10-12 in 3-4 dosing groups)
- Primary endpoint=safety. Secondary endpoints include measures of efficacy
- University of Würzburg Phase I/II unit
- Commence 1HCY2012; 12 month study
- Continuing rolling data
- Estimated cost ≈$1M

# PAT-SC1 (Gastric Cancer)

| | |
|---|---|
| **Overview** | ➢ Pentameric IgM antibody<br>➢ First antibody from pipeline evaluated in clinical trial |
| **Target: CD55** | ➢ Binds to isoform of CD55 expressed on multiple types of cancer cells |
| **Trial Results** | ➢ Safe in 51 patients receiving PAT-SC1<br>➢ Significant 10 year survival benefit for 30 gastric patients with minimal residual disease (R0) post-surgery vs. untreated patients |
| **Current Stage** | ➢ Orphan status confirmed (fast track opportunity in U.S.)<br>➢ Package ready for outlicensing |
| **Competition** | ➢ No other known clinical products targeting CD55 |







*Historic control of 51 patients at same facility receiving same treatment but for PAT-SC1

# PAT-LM1

| | |
|---|---|
| **Overview** | ➢ Pentameric IgM antibody<br>➢ Potent killing activity across multiple cancers |
| **Target: NONO** | ➢ Binds to NONO protein expressed in 98% of over 200 different patient tumours screened<br>➢ Third party research confirms several critical roles of NONO in cancer<br>➢ Further target work ongoing (University Western Australia) |
| **Current Stage** | ➢ Early stages scale-up production |
| **Competition** | ➢ No other known products targeting NONO |






# Plans For 2012

- Complete PAT-SM6 melanoma trial and release full data (1Q12)
- Finalise preclinical work to support a PAT-SM6 multiple myeloma trial
- Commence PAT-SM6 Phase I/IIa open label multi-dose multiple myeloma clinical trial
- Out-license PAT-SC1
- Further prepare PAT-LM1 for clinical trial and/or partnering
- Expand the pipeline through internal R&D
- Publish additional preclinical work on both PAT-SM6 and PAT-LM1

# For Further Information

## Contact Details

- Dr. Marie Roskrow, Chief Executive Officer
- Roger McPherson, Chief Financial Officer
- Ph: +61 3 9670 3273
- Email: info@patrys.com
- Website: www.patrys.com